Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-050926
Filing Date
2022-08-25
Accepted
2022-08-25 07:16:16
Documents
37
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea164764-6k_canfite.htm   iXBRL 6-K 17513
2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2022 ea164764ex99-1_canfite.htm EX-99.1 75983
3 UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 202 ea164764ex99-2_canfite.htm   iXBRL EX-99.2 188622
4 PRESS RELEASE DATED AUGUST 25, 2022 ea164764ex99-3_canfite.htm EX-99.3 62060
  Complete submission text file 0001213900-22-050926.txt   1588950

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE canf-20220630.xsd EX-101.SCH 23966
6 XBRL CALCULATION FILE canf-20220630_cal.xml EX-101.CAL 21880
7 XBRL DEFINITION FILE canf-20220630_def.xml EX-101.DEF 70425
8 XBRL LABEL FILE canf-20220630_lab.xml EX-101.LAB 178225
9 XBRL PRESENTATION FILE canf-20220630_pre.xml EX-101.PRE 74645
31 EXTRACTED XBRL INSTANCE DOCUMENT ea164764-6k_canfite_htm.xml XML 86664
Mailing Address 10 BAREKET STREET, KIRYAT MATALON P.O. BOX 7537 PETACH TIKVA L3 4951778
Business Address 10 BAREKET STREET, KIRYAT MATALON P.O. BOX 7537 PETACH TIKVA L3 4951778 972 39241114
Can-Fite BioPharma Ltd. (Filer) CIK: 0001536196 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36203 | Film No.: 221192966
SIC: 2834 Pharmaceutical Preparations